	US 12,343,324 B2
	Dihydromyricetin hot melt extrusion formulations and methods for forming them
Robert K. Prud'Homme, Princeton, NJ (US); Brooks Powell, Houston, TX (US); Vikram Pansare, Princeton, NJ (US); and Nicholas Caggiano, Princeton, NJ (US)
Assigned to The Trustees of Princeton University, Princeton, NJ (US); and Cheers Health, Inc., Houston, TX (US)
Filed by The Trustees of Princeton University, Princeton, NJ (US); and Cheers Health, Inc., Houston, TX (US)
Filed on Sep. 13, 2022, as Appl. No. 17/943,691.
Application 17/943,691 is a continuation of application No. 16/683,387, filed on Nov. 14, 2019, abandoned.
Claims priority of provisional application 62/767,208, filed on Nov. 14, 2018.
Prior Publication US 2023/0285352 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 9/06 (2006.01); A61K 9/10 (2006.01); A61K 9/16 (2006.01); A61K 9/28 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 9/06 (2013.01); A61K 9/10 (2013.01); A61K 9/1617 (2013.01); A61K 9/1647 (2013.01); A61K 9/2846 (2013.01); A61K 45/06 (2013.01)]

25 Claims

1. A dihydromyricetin (DHM) formulation, comprising:

dihydromyricetin (DHM); and

a matrix material,

wherein the matrix material comprises poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA),

wherein the DHM is dissolved in the matrix material, and

wherein the DHM formulation is homogeneous.